Our laboratory and other groups have shown the expression of the Galectin-3 in androgen-independent prostate cancer cells PC-3 (derived from bone metastasis) and DU-145 (derived from brain metastasis), used in vitro and in xenograft implants, as a CRPC models (50–54). Here, LGALS3 is linked to prostate carcinoma.